Gabapentin May Cut Opioid Needs for Oral Mucositis Pain During RT
Findings seen in studies involving patients receiving chemoradiotherapy for nonmetastatic squamous cell carcinoma of head and neck
Findings seen in studies involving patients receiving chemoradiotherapy for nonmetastatic squamous cell carcinoma of head and neck
Silmitasertib is a first-in-class potent and highly selective inhibitor of casein kinase 2 (CK2).
The phase 3 RATIONALE 309 trial evaluated the efficacy and safety of tislelizumab plus chemotherapy in 263 adults with recurrent or metastatic nasopharyngeal cancer (RM-NPC).
The application is supported by data from the phase 2 POLARIS-02 and phase 3 JUPITER-02 studies.
Study authors analyzed the safety and efficacy of using MMA for patients undergoing head and neck surgery.
However, reductions in oropharynx cancer incidence should be seen among young and middle-aged adults
Therapy intensification with carboplatin improved five-year event-free survival in children with high-risk group 3 medulloblastoma only
Recommendations aim to improve postoperative pain control while reducing the risk for opioid use disorder.
The new dosing schedule is in addition to the approved weekly dosage regimen.
The FDA previously granted Fast Track designation to tipifarnib for this indication.